EchoMD Automated Ejection Fraction Software vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoMD Automated Ejection Fraction Software

by Bay Labs (now Caption Health)

EchoNext

by Pathway Labs

AI Verdict

These tools are adjacent competitors, both operating in the cardiology AI space but with different diagnostic focuses. EchoMD specializes in automating echocardiogram analysis for ejection fraction calculation, ideal for practices focused on cardiac imaging efficiency. EchoNext, conversely, analyzes standard ECGs to detect hidden structural heart disease, making it suitable for broader screening and early detection in various clinical settings.

Choose EchoMD Automated Ejection Fraction Software if…

Choose EchoMD Automated Ejection Fraction Software if your primary need is to automate and standardize the measurement of left ventricular ejection fraction (EF) from echocardiograms. This tool is ideal for cardiology departments and imaging centers looking to improve efficiency and reduce variability in EF calculations through AI-powered clip selection and analysis, integrating directly with existing DICOM PACS systems.

View EchoMD Automated Ejection Fraction Software →

Choose EchoNext if…

Choose EchoNext if your focus is on early detection and screening for hidden structural heart disease using standard ECGs. This tool is best suited for a wide range of clinical settings, from major hospitals to community practices, that aim to identify risks for conditions like heart failure, valve disease, and pulmonary hypertension non-invasively, leveraging AI through the OpenEvidence clinical decision support platform.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoMD Automated Ejection Fraction Software	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	On-premise (via DICOM PACS integration)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoMD Automated Ejection Fraction Software

EchoMD Automated Ejection Fraction Software integrates seamlessly with existing DICOM PACS systems and automates clip selection and EF calculation, streamlining workflow and reducing manual intervention. EchoNext, while offering valuable insights, requires integration with the OpenEvidence platform, which might introduce an additional layer of complexity for some users.

Clinical Value

EchoNext

EchoNext offers broader clinical value by detecting a range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, from a standard ECG, which is a widely available and inexpensive test. This allows for earlier identification of high-risk patients who may not yet be symptomatic. EchoMD focuses on improving the efficiency and accuracy of EF calculation from echocardiograms, a more specialized and less accessible test for initial screening.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, including details on implementation fees and discounts, allowing for clearer budget planning. EchoMD's pricing is only available upon contact, which can make it harder for potential customers to assess its value proposition without direct engagement. EchoNext's use of standard ECGs also presents a potentially more cost-effective screening approach compared to echocardiograms.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness. EchoMD integrates with DICOM PACS systems, a standard in medical imaging, and is FDA cleared and HIPAA compliant. EchoNext is also FDA cleared and HIPAA compliant, and its deployment through the OpenEvidence clinical decision support platform, used by a large number of U.S. physicians, indicates strong potential for broad adoption within health systems.

Innovation

EchoNext

EchoNext represents a significant innovation by enabling the detection of various structural heart diseases from a routine ECG, a capability not traditionally associated with ECGs. This offers a novel approach to widespread screening and early detection. EchoMD's innovation lies in automating and improving the accuracy of an existing echocardiogram measurement, which is an enhancement to an established diagnostic pathway.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the depth or accessibility of support and documentation for either EchoMD Automated Ejection Fraction Software or EchoNext. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoMD Automated Ejection Fraction Software	EchoNext
Tool Name	EchoMD Automated Ejection Fraction Software	EchoNext
Company	Bay Labs (now Caption Health)	Pathway Labs
Tagline	AI-powered automated ejection fraction calculation for echocardiograms.	How's your heart?
Primary Function	Automated Left Ventricular Ejection Fraction (EF) calculation from echocardiograms	AI-powered ECG analysis to detect hidden structural heart disease
Specialties	Cardiology, Critical Care, Emergency Medicine, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring EchoMD Automated Ejection Fraction Software and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

EchoMD Automated Ejection Fraction Software is designed for seamless integration with DICOM PACS systems, providing results as part of the routine diagnostic workflow. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians and offers real-time documentation capabilities.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

EchoMD Automated Ejection Fraction Software has demonstrated less variability in EF measurement (8.29%) compared to the average cardiologist (9.2%), and it performs well across various patient types. EchoNext has shown high accuracy in detecting structural heart disease (SHD) from ECGs, with an AUROC of 85.2% in internal tests and 78-80% in external validation, outperforming cardiologists in identifying SHD.

Which specialties are these tools best suited for, and what clinical context should I consider when choosing?

EchoMD is primarily for cardiology, critical care, emergency medicine, and radiology, focusing on automating EF calculation from echocardiograms to improve efficiency and reduce variability in cardiac evaluation. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to screen for hidden structural heart disease, potentially enabling earlier detection and guiding decisions for further imaging.

What is the learning curve for physicians and support quality for each tool?

EchoMD is designed for easy adoption due to its intuitive design and automated processes for clip selection and EF calculation, allowing clinicians to focus on patient context. While EchoNext's documentation doesn't explicitly detail its learning curve, its integration with the OpenEvidence platform suggests a focus on accessibility and streamlined use within existing clinical decision support workflows.

Are there customer references or case studies available to demonstrate real-world effectiveness and time-to-value?

EchoMD has been validated in studies with institutions like the Minneapolis Heart Institute, demonstrating improved efficiency and reduced variability in EF measurements. EchoNext has undergone extensive clinical validation, including a 100-patient pilot study where 73% of high-risk patients identified by EchoNext were newly diagnosed with SHD, and a large-scale randomized controlled trial (CACTUS) is underway.

What considerations are there for multi-site rollout of these tools?

EchoMD integrates with DICOM PACS systems, which would be a key consideration for multi-site deployments to ensure compatibility across different imaging environments. EchoNext's generalizability has been demonstrated across diverse patient demographics, clinical contexts, and numerous hospitals, with its deployment through the OpenEvidence platform suggesting scalability for broader access from major hospitals to community practices.